Clinical stage drug development company Noxopharm (ASX:NOX) reports it has received confirmation from the DARRT-2 Safety Steering Committee that its VeyondaⓇ drug candidate is safe at a dose of 1600mg.
The decision comes following the treatment of the 3rd cohort of patients as part of the dose escalation stage of the DARRT-2 trial, which is evaluating the company’s clinical drug candidate VeyondaⓇ in combination with low-dose external beam radiotherapy with a focus on the treatment of prostate cancer.
The company says no further dose escalations will occur and it will move forward with part 2 of the efficacy phase, which is scheduled to begin in late Q1/early Q2 2023.
“We are proceeding according to schedule as we now wind down the first part of the trial and look to start focusing on efficacy in the very near future”
Speaking on the trial, Noxopharm Chief Executive Officer Gisela Mautner said: “This meeting marks a positive development in the progress of DARRT-2. We are proceeding according to schedule as we now wind down the first part of the trial and look to start focusing on efficacy in the very near future.
As stated in the recent AGM, we are actively exploring ways to reduce patient numbers and costs while bringing forward efficacy data. And when results are meaningful, we will target data releases via high-profile conferences and peer-reviewed publications to maximise commercial potential.”
DARRT is a phase 1b/2a dose expansion, dose escalation clinical trial in patients with metastatic cancers across multiple sites in the US, Europe and Australia. The trial is examining the combination of VeyondaⓇ with low-dose radiotherapy for the treatment of prostate cancer as the major focus, as well as breast and lung cancer patients on an exploratory basis.
Noxopharm is an innovative Australian biotech company that is focused on the discovery and development of novel treatments for cancer and inflammation. The company currently has 3 active drug development programs, the lead clinical-stage drug candidate VeyondaⓇ, and 2 innovative technology platforms Chroma(™) (oncology) and Sofra(™) (inflammation and autoimmunity).
These development programs provide the basis for active development of a growing pipeline of new proprietary drugs.